New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTVCYT, VCYT, VCYTVeracyte management to meet with Leerink
Meetings to be held in New York on April 14 and in New York/Connecticut on April 15 hosted by Leerink.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
07:14 EDTVCYTCMS decision removes potential headwind for Veracyte, says Stephens
Stephens analyst Drew Jones noted that an updated CLFS with 2016 determinations released by CMS suggests a change to gap fill pricing for Veracyte's Afirma GEC test, removing what could have been a significant headwind heading into 2016. Jones maintains his Overweight rating and $14 price target on Veracyte shares.
November 17, 2015
20:06 EDTVCYTVeracyte applauds CMS decision to use 'gapfill' pricing for Afirma
Veracyte issued a statement in response to the Centers for Medicare and Medicaid Services', or CMS, decision to use a "gapfill" approach to pricing the Afirma Gene Expression Classifier, or GEC. CMS's final decision was published in its 2016 Clinical Laboratory Fee Schedule, or CLFS, Final Determinations and reverses the agency's previous proposal to "crosswalk" the price of the Afirma GEC to that of a very different test, which would have resulted in a lower 2016 Medicare reimbursement rate for the Afirma GEC. "We applaud CMS for its decision, which we believe recognizes the unique nature of the Afirma GEC, including its unmatched ability to rule out cancer in thyroid nodules that are deemed inconclusive following initial, traditional evaluation," said Veracyte CEO Bonnie Anderson. "Today's decision is a victory for precision medicine and the many patients who are benefitting from it. We estimate that the Afirma GEC, for example, has helped tens of thousands of patients avoid unnecessary thyroid surgery and its potential aftermath, while avoiding millions of dollars of unnecessary healthcare spending."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use